Blog

DEEP RESEARCH · SAMSUNG EPIS HOLDINGS

Samsung Epis Holdings: Strategic Meaning of Samsung Biologics' Spin-Off

A structured view of the separation between CDMO and biosimilar/new-drug development.

Published: 2025-11-27 · Spin-off analysis · Naver Blog source

Investment decisions are your responsibility. This material is research and is not a recommendation to buy or sell.

0. Bottom line first

The core of the split is to make Samsung Biologics a pure-play CDMO while positioning Samsung Epis Holdings as a bio-investment holding company that combines Samsung Bioepis' biosimilar cash generation with investment in next-generation platforms such as ADCs. I see this less as a cosmetic governance move and more as a commercial strategy to reduce customer conflict-of-interest concerns.

Attached audio: Samsung Biologics split, trust, and future technology bet.mp3

Official fact: The source cites the planned November 1, 2025 spin-off, creation of Samsung Epis Holdings, and Samsung Bioepis' 3Q 2025 cumulative revenue of KRW 1.1403 trillion and operating profit of KRW 305.9 billion.

Interpretation: The structure removes the discomfort CDMO customers may feel when a biosimilar developer sits under the same ownership roof, while giving the Epis side independence for higher-risk, higher-return capital allocation.

Samsung Biologics Spin-OffSeparating CDMO from product development
Surviving companySamsung Biologics · pure-play CDMO
New companySamsung Epis Holdings · bio-investment holdco
SubsidiarySamsung Bioepis · biosimilar cash cow
New investmentADC and next-generation platforms
The key question is whether both businesses can earn better stand-alone valuations.

1. Why split?

Official fact: The source says conflict between CDMO customer IP and biosimilar competition became a real sales barrier after Samsung Biologics made Samsung Bioepis a wholly owned subsidiary in 2022.

  • In the source's case A, a production contract for drug B required separation of production facilities and quality testing because Samsung Bioepis was developing a biosimilar to the same drug.
  • In case C, biosimilar development for drugs D and E delayed a contract process.
  • In case F, a global pharma company reportedly refused contract discussions because it viewed Samsung Biologics and Samsung Bioepis as effectively the same entity.

Interpretation: CDMO is a trust business that handles customer IP. Even with legal firewalls, ownership links can become a psychological barrier. The split is therefore a costly but commercially rational step.

2. Roles after the split

Samsung Biologics

Stable infrastructure business

Focuses on CDMO with large-scale facilities and long-term contracts. The source highlights global leading capacity, Plant 5, and future facilities.

Samsung Epis Holdings

Growth bio holdco

Uses Samsung Bioepis' cash generation to invest in biosimilars, new drugs, and next-generation platforms such as ADCs.

3. Financial structure and valuation

ItemSource figureMeaning
Samsung Bioepis 3Q 2025 cumulative revenueKRW 1.1403 trillionStand-alone revenue base
Samsung Bioepis 3Q 2025 cumulative operating profitKRW 305.9 billionCash generation proven
Estimated Samsung Epis Holdings assetsAbout KRW 3.36 trillionM&A and R&D capacity
Estimated Samsung Epis Holdings liabilitiesAbout KRW 9 billionDebt ratio around 0.3%
Estimated Samsung Biologics assets/liabilities/equityAbout KRW 9.98T / 3.74T / 6.24TLow leverage for a capex-heavy company

Interpretation: Samsung Epis Holdings is naturally valued through SOTP: Samsung Bioepis equity value plus new subsidiaries plus net cash, less a holding-company discount.

4. Risks

  • Trading volatility after the split and relisting.
  • A holding-company discount may apply.
  • If Samsung Bioepis prioritizes R&D reinvestment, dividends to the holdco may be limited.
  • Biosimilar price competition is intensifying.
  • ADC and other new technologies have upside, but high failure risk.

5. My conclusion

I would watch two things. First, whether Samsung Biologics converts conflict-of-interest removal into visible global pharma orders. Second, whether Samsung Epis Holdings can avoid being treated as a simple discounted holdco by proving a credible bridge between biosimilar cash flow and ADC platform investment.

Sources

Naver original